RT Journal Article
T1 The Role of Collectins and Galectins in Lung Innate Immune Defense
A1 Casals Carro, María Cristina
A1 Campanero-Rhodes, María
A1 García-Fojeda García-Valdecasas, María Belén
A1 Solís, Dolores
AB Different families of endogenous lectins use complementary defense strategies against pathogens. They may recognize non-self glycans typically found on pathogens and/or host glycans. The collectin and galectin families are prominent examples of these two lectin categories. Collectins are C-type lectins that contain a carbohydrate recognition domain and a collagen-like domain. Members of this group include surfactant protein A (SP-A) and D (SP-D), secreted by the alveolar epithelium to the alveolar fluid. Lung collectins bind to several microorganisms, which results in pathogen aggregation and/or killing, and enhances phagocytosis of pathogens by alveolar macrophages. Moreover, SP-A and SP-D influence macrophage responses, contributing to resolution of inflammation, and SP-A is essential for tissue-repair functions of macrophages. Galectins also function by interacting directly with pathogens or by modulating the immune system in response to the infection. Direct binding may result in enhanced or impaired infection of target cells, or can have microbicidal effects. Immunomodulatory effects of galectins include recruitment of immune cells to the site of infection, promotion of neutrophil function, and stimulation of the bactericidal activity of infected macrophages. Moreover, intracellular galectins can serve as danger receptors, promoting autophagy of the invading pathogen. This review will focus on the role of collectins and galectins in pathogen clearance and immune response activation in infectious diseases of the respiratory system.
PB Frontiers
SN 1664-3224
YR 2018
FD 2018
LK https://hdl.handle.net/20.500.14352/94516
UL https://hdl.handle.net/20.500.14352/94516
LA eng
NO Casals C, Campanero-Rhodes MA, García-Fojeda B and Solís D (2018) The Role of Collectins and Galectins in Lung Innate Immune Defense. Front. Immunol. 9:1998. doi: 10.3389/fimmu.2018.01998  Received: 17 June 2018; Accepted: 14 August
NO Ministerio de Economía y Competitividad (España)
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 10 abr 2025